The estimated Net Worth of Mitchell Mutz is at least $601 Mille dollars as of 21 July 2020. Mitchell Mutz owns over 46,111 units of Pandion Therapeutics stock worth over $600,500 and over the last 4 years Mitchell sold PAND stock worth over $0.
Sign up
Mitchell Mutz PAND stock SEC Form 4 insiders trading
Mitchell has made over 1 trades of the Pandion Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Mitchell bought 46,111 units of PAND stock worth $829,998 on 21 July 2020.
The largest trade Mitchell's ever made was buying 46,111 units of Pandion Therapeutics stock on 21 July 2020 worth over $829,998. On average, Mitchell trades about 23,056 units every 0 days since 2020. As of 21 July 2020 Mitchell still owns at least 10,000 units of Pandion Therapeutics stock.
You can see the complete history of Mitchell Mutz stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Mitchell Mutz's mailing address?
Mitchell's mailing address filed with the SEC is C/O PANDION THERAPEUTICS, INC.,, 134 COOLIDGE AVENUE, WATERTOWN, MA, 02472.
Insiders trading at Pandion Therapeutics
Over the last 4 years, insiders at Pandion Therapeutics have traded over $0 worth of Pandion Therapeutics stock and bought 1,743,632 units worth $30,815,954 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Kol... e Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $9,518,646. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth $2,989,466.
What does Pandion Therapeutics's logo look like?
Complete history of Mitchell Mutz stock trades at Pandion Therapeutics
Pandion Therapeutics executives and stock owners
Pandion Therapeutics executives and other stock owners filed with the SEC include:
-
Capital Management, L.P.Kol...,
-
Nancy Stagliano,
Director -
Vikas Goyal,
See Remarks -
Joanne L. Viney,
See Remarks -
Partners Gp Viii, L.L.C.Pol...,
-
Rizzuto Carlo,
Director -
Jill Carroll,
Director -
Katina Dorton,
Director -
Donald Frail,
Director -
Christopher Fuglesang,
Director -
Gregg Beloff,
See Remarks -
Alan L Crane,
Director -
Mitchell Mutz,
Director -
Eric D Larson,
Vice President, Finance -
Daniel J. Becker,
Director -
Rahul Kakkar,
Chief Executive Officer -
Plc Gsk,
Director -
John Sundy,
Chief Medical Officer -
Edward D. Freedman,
Chief Operating Officer